Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet

Clinical Pharmacology and Therapeutics

Volumn 72, Issue 1, 2002, Pages 50-61

  Schwartz, J I ^a,b,c   Vandormael, K ^a,b,c   Malice, M P ^a,b,c   Kalyani, R N ^a,b,c   Lasseter, K C ^a,b,c   Holmes, G B ^a,b,c   Gertz, B J ^a,b,c   Gottesdiener, K M ^a,b,c   Laurenzi, M ^a,b,c   Redfern, K J ^a,b,c   Brune, K ^a,b,c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b SFBC International   (United States)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CREATININE; CYCLOOXYGENASE 2 INHIBITOR; NAPROXEN; ROFECOXIB;

ADULT; AGED; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DIETARY INTAKE; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; POTASSIUM URINE LEVEL; PRIORITY JOURNAL; SODIUM URINE LEVEL; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

AGED; AGED, 80 AND OVER; BLOOD PRESSURE; BODY WEIGHT; CREATININE; CYCLOOXYGENASE INHIBITORS; DIET; DOUBLE-BLIND METHOD; ELECTROLYTES; FEMALE; HUMANS; KIDNEY; LACTONES; MALE; MIDDLE AGED; NAPROXEN; POTASSIUM; PYRAZOLES; SODIUM; SODIUM CHLORIDE, DIETARY; SULFONAMIDES; SULFONES;

EID: 0036339070     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.126182     Document Type: Article

References (61)

1. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein
2. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase
3. TIS 10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue
4. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isoenzymes by aspirin and other nonsteroidal anti-inflammatory drugs
5. Selective inhibition of inducible cyclooxygenase-2 in vivo is anti-inflammatory and non-ulcerogenic
6. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: A novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach
7. Cyclooxygenase-2 and its regulation in inflammation
8. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
9. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
10. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomized double-blind comparison
11. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS Study: A randomized, controlled trial
12. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: Implication for renal function
13. Immunohistochemical localization of the prostaglandin-forming cyclooxygenase in renal cortex
14. Renal identification of cyclooxygenase-2 in a subset of thick ascending limb cells
15. Cyclo-oxygenase-1 is associated with the macula densa of rat kidney and increases with salt restriction
16. Regulation of cyclooxygenase expression in the kidney by dietary salt intake
17. Interspecies differences in renal localization of cyclooxygenase isoforms: Implications in nonsteroidal antiinflammatory drug-related nephropathy
18. Differential regulation of renal cyclooxygenase mRNA by dietary salt intake
19. Cloning, expression, and regulation of rabbit cyclooxygenase-2 in renal medullary interstitial cells
20. Angiotensin II stimulates renal cortical cyclooxygenase-2 expression
21. Selective increase of cyclooxygenase-2 expression in model of renal ablation
22. Coordinate expression of cyclooxygenase-2 and renin in the rat kidney in renovascular hypertension
23. Up regulation of renal and systemic cyclo-oxygenase-2 in patients with active lupus nephritis
24. Immunolocalization of cyclooxygenase-2 in the macula densa of human elderly
25. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects
26. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet
27. Renal effects of COX-2-selective inhibitors
28. Renal complications associated with use of nonsteroidal anti-inflammatory agents
29. Renal toxicity of the nonsteroidal anti-inflammatory drugs
30. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor
31. NSAIDs and the kidney revisited: Are selective cyclooxygenase-2 inhibitors safe?
32. Selective cyclooxygenase inhibitors: A pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs
33. COX-2 inhibitor acute renal failure: Association with hyperkalemia and type IV renal tubular acidosis
34. Celecoxib-induced acute renal failure
35. Acute renal failure induced by COX-2 specific inhibitors
36. Do COX-2 inhibitors induce more hyponatremia than nonselective NSAIDs?
37. Changes in renal function with aging
38. Prediction of creatinine clearance from serum creatinine
39. Acute and chronic effects of nonsteroidal antiinflammatory drugs on glomerular filtration rate in elderly patients
40. The effect of nonsteroidal anti-inflammatory drugs on electrolyte homeostasis and blood pressure in young and elderly persons with and without renal insufficiency
41. Increased salt retention and hypertension from non-steroidal agents in the elderly
42. Effects of celecoxib and naproxen on renal function in the elderly
43. 2 across the isolated perfused rabbit collecting tubule
44. Nephron site of non-steroidal anti-inflammatory drugs on solute excretion in humans
45. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: An under-recognized public health problem
46. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics
47. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids
48. Elevated systolic blood pressure and risk of cardiovascular and renal disease: Overview of evidence from observational epidemiologic studies and randomized controlled trials
49. Risk reduction associated with lowering systolic blood pressure: Review of clinical trial data
50. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis
51. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure
52. Cyclooxygenase-2-specific inhibitors and cardiorenal function: A randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients
53. A clinical trial comparing rofecoxib, celecoxib and acetaminophen in osteoarthritis of the knee - A randomized trial
54. Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry
55. Selective and rapid liquid chromatography-mass spectrometry